Vascular Biogenics (NASDAQ:VBLT) Stock Rating Upgraded by Chardan Capital

Vascular Biogenics (NASDAQ:VBLT) was upgraded by stock analysts at Chardan Capital from a “neutral” rating to a “buy” rating in a research report issued to clients and investors on Thursday, The Fly reports. The brokerage presently has a $3.25 target price on the biopharmaceutical company’s stock. Chardan Capital’s target price points to a potential upside of 173.11% from the stock’s previous close.

VBLT has been the subject of a number of other reports. ValuEngine cut Vascular Biogenics from a “hold” rating to a “sell” rating in a research note on Thursday. Zacks Investment Research cut Vascular Biogenics from a “hold” rating to a “sell” rating in a research note on Thursday, August 29th. Two investment analysts have rated the stock with a sell rating and four have assigned a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average price target of $2.44.

Shares of NASDAQ VBLT traded down $0.04 during trading hours on Thursday, reaching $1.19. 43,200 shares of the stock were exchanged, compared to its average volume of 30,020. Vascular Biogenics has a 52 week low of $0.60 and a 52 week high of $1.90. The firm has a market capitalization of $44.13 million, a price-to-earnings ratio of -1.92 and a beta of -0.29. The company has a debt-to-equity ratio of 0.05, a quick ratio of 6.45 and a current ratio of 6.45. The stock’s fifty day simple moving average is $1.27 and its 200 day simple moving average is $1.26.

Vascular Biogenics (NASDAQ:VBLT) last announced its quarterly earnings results on Thursday, November 14th. The biopharmaceutical company reported ($0.14) EPS for the quarter, meeting the Zacks’ consensus estimate of ($0.14). Vascular Biogenics had a negative return on equity of 35.64% and a negative net margin of 3,050.43%. The company had revenue of $0.08 million during the quarter, compared to analysts’ expectations of $0.24 million. Research analysts predict that Vascular Biogenics will post -0.53 EPS for the current fiscal year.

Several institutional investors and hedge funds have recently made changes to their positions in VBLT. Athena Capital Advisors LLC lifted its stake in shares of Vascular Biogenics by 216.7% in the 2nd quarter. Athena Capital Advisors LLC now owns 35,000 shares of the biopharmaceutical company’s stock valued at $46,000 after acquiring an additional 23,950 shares during the last quarter. Morgan Stanley lifted its stake in shares of Vascular Biogenics by 6.5% in the 2nd quarter. Morgan Stanley now owns 295,012 shares of the biopharmaceutical company’s stock valued at $383,000 after acquiring an additional 17,900 shares during the last quarter. Finally, Ladenburg Thalmann Financial Services Inc. lifted its stake in shares of Vascular Biogenics by 66.7% in the 2nd quarter. Ladenburg Thalmann Financial Services Inc. now owns 37,500 shares of the biopharmaceutical company’s stock valued at $49,000 after acquiring an additional 15,000 shares during the last quarter. Institutional investors own 5.38% of the company’s stock.

About Vascular Biogenics

Vascular Biogenics Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for cancer. The company's program is based on its proprietary vascular targeting system platform technology, which utilizes genetically targeted therapy to destroy newly formed or angiogenic blood vessels.

Read More: Sell-Side Analysts

The Fly

Receive News & Ratings for Vascular Biogenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vascular Biogenics and related companies with MarketBeat.com's FREE daily email newsletter.